Effect of anticoagulant therapy on the hypercoagulable state in patients carrying the factor V Arg506Gln mutation.
Resistance to activated protein C, caused by a single point mutation in the factor V gene (Arg506Gln or FV Leiden), is the most prevalent single risk factor associated with venous thromboembolic disease. The aim of this study was to investigate the effectiveness of standard oral anticoagulant therapy (OAT) in patients with the Arg506Gln mutation compared with a matched control group. The study compared selected variables in 27 patients carrying the Arg506Gln mutation with 27 sex- and age-matched controls in steady state oral anticoagulant treatment (OAT). The study showed that similar doses of vitamin K antagonists in carriers and noncarriers suppress and generate a uniform distribution of coagulation markers in steady state OAT. Thus, it seems that OAT with standard treatment doses is just as effective in patients with the Arg506Gln mutation as in comparable controls without the mutation.
Larsen
T B
TB
Department of Clinical Biochemistry, Vejle County Central Hospital, Denmark. tblarsen@dadlnet.dk
Lassen
J F
JF
Dahler-Eriksen
B S
BS
Petersen
P H
PH
Brandslund
I
I
D020016:Activated Protein C Resistance / Q000188:drug therapy* / Q000235:genetics*; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000627:therapeutic use*; D001120:Arginine; D016022:Case-Control Studies; D005165:Factor V / Q000235:genetics*; D005260:Female; D005998:Glycine; D006801:Humans; D007124:Immunoenzyme Techniques; D016014:Linear Models; D008297:Male; D008875:Middle Aged; D010644:Phenprocoumon / Q000627:therapeutic use; D017354:Point Mutation; D016133:Polymerase Chain Reaction; D018709:Statistics, Nonparametric; D014859:Warfarin / Q000627:therapeutic use
D000925:Anticoagulants; D014859:Warfarin; D005165:Factor V; D001120:Arginine; D010644:Phenprocoumon; D005998:Glycine